# Junta clínica — PT-pseudo_938ba8a478e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_938ba8a478e6",
  "pid": "PT-pseudo_938ba8a478e6",
  "task": 1,
  "psa": 7.9,
  "age": 65,
  "months": 1,
  "pirads": "4",
  "psad": 0.07,
  "psav": 2.6,
  "psap": 5.6,
  "vol": 123.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.76090467,
  "medhx": "Hypertension, COPD, Chronic kidney disease",
  "meds": "amlodipine, valsartan, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 7.9 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 123 mL. csPCa 0.76.",
  "pmhx": [
    "Hypertension",
    "COPD",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "180 cm",
    "bmi": "24.1",
    "bp": "123/70 mmHg",
    "hr": "83 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinician review requested due to escalating antigen levels alongside a previously confirmed malignant biopsy."
    },
    {
      "s": "History",
      "t": "Aged 65 and employed as an office administrator, the individual resides solo, with his nephew designated as next of kin. A married non-smoker, his initial workup commenced in late 2022 following an elevated antigen reading. Chronic conditions include hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Current pharmacotherapy encompasses amlodipine, valsartan, metoprolol, tiotropium, and salbutamol administered on an as-needed basis. Lower urinary tract complaints register at 8 on the IPSS scale, yet recreational cycling persists at roughly 30 kilometres three times weekly. Recent outpatient visits to gastroenterology for routine colonoscopy and to endocrinology for thyroid evaluation both returned negative findings. Aside from minor visual deficits necessitating large-print materials, systemic complaints, bone discomfort, and urinary blood are denied. Workplace and domestic environments present no notable stressors. Alcohol consumption remains low at two weekly units. The subject maintains full independence in daily routines. A systematic transrectal ultrasound biopsy performed in early 2023 yielded Gleason 4+3 pathology."
    },
    {
      "s": "Physical examination",
      "t": "DRE — consistency: smooth and firm; symmetry: preserved; nodularity: absent. General inspection reveals clear pulmonary fields and a regular cardiac rhythm aligning with his established cardiovascular baseline. Abdominal palpation demonstrates a soft, non-tender contour devoid of masses or organomegaly."
    }
  ],
  "occupation": "office administrator",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "2 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 8/35 (moderate LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Tergooi MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_938ba8a478e6
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 7.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 2.6 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 123.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.76090467 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD, Chronic kidney disease
  - Problem list / PMHx: Hypertension, COPD, Chronic kidney disease
  - Current medication: amlodipine, valsartan, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7.9 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 123 mL. csPCa 0.76.

Vitals: weight 78 kg, height 180 cm, BMI 24.1, BP 123/70 mmHg, HR 83 bpm. Smoking: Non-smoker.

Chief complaint: Clinician review requested due to escalating antigen levels alongside a previously confirmed malignant biopsy.

History: Aged 65 and employed as an office administrator, the individual resides solo, with his nephew designated as next of kin. A married non-smoker, his initial workup commenced in late 2022 following an elevated antigen reading. Chronic conditions include hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Current pharmacotherapy encompasses amlodipine, valsartan, metoprolol, tiotropium, and salbutamol administered on an as-needed basis. Lower urinary tract complaints register at 8 on the IPSS scale, yet recreational cycling persists at roughly 30 kilometres three times weekly. Recent outpatient visits to gastroenterology for routine colonoscopy and to endocrinology for thyroid evaluation both returned negative findings. Aside from minor visual deficits necessitating large-print materials, systemic complaints, bone discomfort, and urinary blood are denied. Workplace and domestic environments present no notable stressors. Alcohol consumption remains low at two weekly units. The subject maintains full independence in daily routines. A systematic transrectal ultrasound biopsy performed in early 2023 yielded Gleason 4+3 pathology.

Physical examination: DRE — consistency: smooth and firm; symmetry: preserved; nodularity: absent. General inspection reveals clear pulmonary fields and a regular cardiac rhythm aligning with his established cardiovascular baseline. Abdominal palpation demonstrates a soft, non-tender contour devoid of masses or organomegaly.

Patient info: office administrator; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 8/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.11 epistemic (95% band 0.34-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.94: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  2. distance 0.96: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  3. distance 1.12: PI-RADS 4, PSA 8.4, PSAD 0.1, age 63, DRE Normal -> BIOPSY (uncertain). He wrote: "Patient on Active surveillance. Initial ISUP and MRI is needed."

PRECEDENT: BIOPSY (weighted vote 0.65 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the use of MRI and biopsy in the context of prostate cancer risk stratification. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." This suggests that the MRI findings, particularly the PI-RADS score, are central to determining the need for further tissue sampling.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I find the suggestion of biopsy is not decisively supported by the guideline because the guideline focuses on risk stratification based on MRI and PSA density, not on the presence of a prior positive biopsy. EXPERT-COHORT, the finding that the prior biopsy status does not determine the decision is consistent with the guideline's focus on current risk factors. EXPERT-LIBRARY, the precedents show varied decisions (DEFER vs. BIOPSY) based on specific combinations of PI-RADS and PSA, indicating that no single precedent dictates the action for this patient.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: a rising PSA velocity is a factor that must be considered in the risk assessment
laboratory_results - the PSA density: the PSA density is a factor that must be considered in the risk assessment

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the implications of the PSA velocity as per the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension require a repeat biopsy?
  psa_trend (get_psa_trend) -> Does the PSA velocity indicate a need for further tissue sampling?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, and is there a surveillance protocol in place?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented ISUP grade of the prior biopsy?
  Q2. Does the PSA velocity indicate a need for further tissue sampling according to the guideline?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size 18 x 14 x 16 mm in the right mid-gland peripheral zone.
psa_trend
Does the PSA velocity indicate a need for further tissue sampling? The PSA velocity shows a rise from 2.1 (Dec 2022) to 7.9 (Jan 2025), indicating a rising trend.
previous_notes
What is the documented grade of the prior biopsy, and is there a surveillance protocol in place? The documented grade of the prior biopsy is Gleason 4+3 pathology from a systematic transrectal ultrasound biopsy performed in early 2023. No explicit surveillance protocol is mentioned in the notes.

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, and the mpMRI prose were not opened because the required information was already extracted from the other documents or is not required for the immediate decision based on the open questions.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI shows a PI-RADS 4 lesion with restricted diffusion, suggesting high suspicion.
The PSA velocity indicates a rising trend, which is a factor to consider in risk assessment.
AGAINST sampling this patient now
The prior biopsy yielded a Gleason 4+3 pathology, which is a known outcome.
No explicit surveillance protocol is mentioned in the notes.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.90 ng/mL over 4 points spanning 25 months; velocity +2.76 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 11.9 ng/mL, conformal 95% band 3.4-41.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.54
  uncertainty  +/- 0.10 epistemic (95% band 0.35-0.74), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.54  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.65  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.55 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions to the extent that the information was extracted from the retrieved documents.

ALIGNMENT WITH THE PANEL
The panel protocol suggests BIOPSY based on a weighted vote, and the retrieved information, specifically the rising PSA velocity and the prior Gleason 4+3 pathology, creates an unclear situation, leaning towards the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented ISUP grade of the prior biopsy? The registrar reported the documented grade as Gleason 4+3 pathology.
Q2. Does the PSA velocity indicate a need for further tissue sampling according to the guideline? The registrar noted the PSA velocity shows a rise from 2.1 to 7.9, indicating a rising trend.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 4+3) is highly relevant as it represents a known outcome, while the rising PSA velocity is relevant as it indicates disease behavior.

MY SUGGESTION TO THE CHAIR
Given the known prior pathology and the rising PSA velocity, the decision remains unclear, but the panel's weighted vote for biopsy is supported by the combination of high PI-RADS and rising PSA. I suggest proceeding with a biopsy to confirm the trajectory.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

65y male, PSA 7.9, PSAD 0.07, PI-RADS 4, on AS with prior positive biopsy, but prior ISUP grade is not recorded. Rising PSA velocity argues for tissue sampling to determine management. Low PSAD argues for observation, but the lack of prior grade necessitates sampling for definitive risk stratification. Alternative plan is delaying for one year.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
